Relay Therapeutics Stock Investor Sentiment
| RLAY Stock | USD 4.86 0.11 2.32% |
Slightly above 58% of all Relay Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Relay Therapeutics suggests that some traders are interested. Relay Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Relay Therapeutics' earnings reports, geopolitical events, and overall market trends.
Relay |
Relay Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Relay Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Relay Therapeutics that are available to investors today. That information is available publicly through Relay media outlets and privately through word of mouth or via Relay internal channels. However, regardless of the origin, that massive amount of Relay data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Relay Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Relay Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Relay Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Relay Therapeutics alpha.
Relay Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Relay upgraded by Jefferies, downgraded by Oppenheimer | 09/10/2024 |
2 | Disposition of 1657 shares by Peter Rahmer of Relay Therapeutics at 11.16 subject to Rule 16b-3 | 09/23/2024 |
3 | Driehaus Capital Management LLC Purchases 218,302 Shares of Relay Therapeutics, Inc. - MarketBeat | 09/30/2024 |
4 | Relay Therapeutics executive sells shares worth over 4,800 | 10/01/2024 |
5 | Relay Therapeutics Receives Buy Rating from HC Wainwright | 10/14/2024 |
6 | Disposition of 1632 shares by Adams Brian of Relay Therapeutics at 6.06 subject to Rule 16b-3 | 10/28/2024 |
7 | Disposition of 2300 shares by Thomas Catinazzo of Relay Therapeutics at 5.95 subject to Rule 16b-3 | 10/29/2024 |
8 | Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 | 10/30/2024 |
9 | Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights | 11/06/2024 |
10 | Relay Therapeutics SWOT analysis PI3K inhibitor progress fuels stock potential | 11/13/2024 |
11 | Down -23.95 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround | 11/19/2024 |
12 | Disposition of 19864 shares by Peter Rahmer of Relay Therapeutics at 6.47 subject to Rule 16b-3 | 11/25/2024 |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.